Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial

Research output: Contribution to journalJournal articlepeer-review

  • Mette Bjerre
  • Hilden, Jørgen
  • Jens Kastrup
  • Maria Skoog
  • Jørgen F Hansen
  • Hans J Kolmos
  • Gorm B Jensen
  • Erik Kjøller
  • Per Winkel
  • Allan Flyvbjerg
  • Christian Gluud
  • CLARICOR Trial Group

OBJECTIVES: To elucidate the prognostic power of serum osteoprotegerin (OPG) in patients with stable coronary artery disease (CAD).

METHODS: Serum OPG levels were measured in the CLARICOR trial cohort of 4063 patients with stable CAD on blood samples drawn at randomization. The follow-up was 2.6 years for detailed cardiovascular events and 6 years for all-cause mortality.

RESULTS: OPG levels were significantly increased in non-survivors (21%) compared to survivors (median [quartiles] 2092 ng/L [1636; 2800] compared to 1695 ng/L [1322; 2193, p < 0.0001]). The 2.6-year follow-up showed that OPG adds to the prediction of both cardiovascular and all-cause mortality in combination with clinical risk factors (HR [one log10 unit increase] 6.1 [95% CI 2.4-15.6, p = 0.0001]) and HR 6.5 [95% CI 3.4-12.5, p < 0.0001], respectively). Similar, in the 6-year follow-up, OPG was found to be a strong predictor for all-cause mortality. Importantly, OPG remained an independent predictor of mortality even after adjustment for both clinical and conventional cardiovascular risk markers (HR 2.5 [95% CI 1.6-3.9, p < 0.0001]).

CONCLUSIONS: Serum OPG has a long-lasting independent predictive power as to all-cause mortality and cardiovascular death in patients with stable CAD.

Original languageEnglish
JournalScandinavian Journal of Clinical & Laboratory Investigation
Volume74
Issue number8
Pages (from-to)657-664
Number of pages8
ISSN0036-5513
DOIs
Publication statusPublished - Nov 2014

ID: 135186856